Spectrum of Respiratory Involvement in Ehlers-Danlos Syndrome: Insights From a Case Report
Abstract
Vascular Ehlers-Danlos syndrome (vEDS) is a rare connective tissue disorder characterized by type III collagen deficiency and marked vascular fragility, which can lead to atypical thoracic manifestations and diagnostic uncertainty. We report a 30-year-old man who initially presented with an ischemic stroke due to arterial dissection and was later diagnosed with vEDS following identification of a pathogenic COL3A1 variant. During follow-up, he developed a large cavitary lung lesion initially treated as an abscess, as well as multiple bilateral pulmonary nodules, some cavitated or surrounded by ground-glass halos, that raised concern for malignancy or infection. Extensive workup with PET/CT, bronchoscopy, and comprehensive microbiologic, cytologic, and immunologic testing was inconclusive, and invasive procedures were avoided because of the high bleeding risk. The multidisciplinary team concluded that the findings were intrapulmonary hematomas from vascular fragility. This case emphasizes the need to consider vEDS-related vascular complications in atypical pulmonary lesions to avoid harmful interventions, and highlights the importance of coordinated, multidisciplinary management.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.